Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Phantom, May I ask you a question? PR said “The financial flexibility provided by this transaction will further support the advancement of our clinical programs including the first Marker-sponsored clinical trial this year investigating our novel MultiTAA cell therapy".
The phrase "first Marker-sponsored clinical trial" leads me to something others (and maybe you) have touched on, and I'd like to ask you about two aspects of it.

#1, Others have suggested that "our" trials are NOT MRKR's trials but are Baylor trials and that may be why we are not properly valued to what we believe we should be.
Is that true? or can you elaborate on it.

#2, and for this I kind of have to stretch to my point. OK, remember for the pancreatic trial MRKR did NOT use a "customized" antigen mix, but rather used the same 5 antigen mix that they were using for AML?

With this "first Marker-sponsored clinical trial", being that this trial will now be MRKR's, no matter what the indication that they will be going after, do you think MRKR will do the smart/right/correct thing and use a "customized" antigen mix?

Thank You
Anybody else please feel free to comment also. Thank You